|
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
1 |
[GO] |
2024―Sep―29 |
Computational targeting of iron uptake proteins in Covid-19 induced mucormycosis to identify inhibitors via molecular dynamics, molecular mechanics and density function theory studies |
Manjima Sen, B. M. Priyanka, D. Anusha, S. Puneetha, Anagha S. Setlur, Chandrashekar Karunakaran, Amulya Tandur, C. S. Prashant, Vidya Niranjan |
2 |
[GO] |
2024―Aug―16 |
In silico analysis of balsaminol as anti-viral agents targeting SARS-CoV-2 main protease, spike receptor binding domain and papain-like protease receptors |
Daniel Danladi Gaiya, Aliyu Muhammad, Joy Sim Musa, Richard Auta, Anthony John Dadah, Rachael Oluwafunmilayo Bello, Madinat Hassan, Samuel Sunday Eke, Rebecca Imoo Odihi, Musa Sankey |
3 |
[GO] |
2024―Mrz―28 |
Exploring the viability of Zeatin as a prospective therapeutic candidate for investigating the complex interplay between severe acute respiratory syndrome coronavirus (SARS-CoV) and Alzheimer’s disease |
A. S. Sriranjini, Ashish Thapliyal, Kumud Pant |
4 |
[GO] |
2024―Feb―27 |
Steroidal lactones from Withania somnifera effectively target Beta, Gamma, Delta and Omicron variants of SARS-CoV-2 and reveal a decreased susceptibility to viral infection and perpetuation: a polypharmacology approach |
Aditi Srivastava, Rumana Ahmad, Irshad A. Wani, Sahabjada Siddiqui, Kusum Yadav, Anchal Trivedi, Shivbrat Upadhyay, Ishrat Husain, Tanveer Ahamad, Shivanand S. Dudhagi |
5 |
[GO] |
2023―Dez―02 |
Design and study of bioisosteric analogues of the drug Molnupiravir as potential therapeutics against SARS-COV-2: an in silico approach |
Donia Ghedira, Abderrazak Aziz El Harran, Houyem Abderrazak |
6 |
[GO] |
2023―Jul―27 |
Development of conserved multi-epitopes based hybrid vaccine against SARS-CoV-2 variants: an immunoinformatic approach |
Allah Rakha Yaseen, Muhammad Suleman, Abdul Salam Qadri, Ali Asghar, Iram Arshad, Daulat Munaza Khan |
7 |
[GO] |
2023―Apr―28 |
Exploring the pharmacological aspects of natural phytochemicals against SARS-CoV-2 Nsp14 through an in silico approach |
Arkajit De, Somdatta Bhattacharya, Bishal Debroy, Arijit Bhattacharya, Kuntal Pal |
8 |
[GO] |
2022―Jul―26 |
Identification of vaccine candidate against Omicron variant of SARS-CoV-2 using immunoinformatic approaches |
Ruchika Sharma, C. R. Patil, Anoop Kumar, Kalicharan Sharma |
9 |
[GO] |
2022―Mrz―14 |
Inhibitory effects of selected isoquinoline alkaloids against main protease (Mpro) of SARS-CoV-2, in silico study |
Morteza Sadeghi, Mehran Miroliaei |
10 |
[GO] |
2021―Aug―07 |
Identification of lead compounds from large natural product library targeting 3C-like protease of SARS-CoV-2 using E-pharmacophore modelling, QSAR and molecular dynamics simulation |
Olusola Olalekan Elekofehinti, Opeyemi Iwaloye, Olorunfemi R. Molehin, Courage D. Famusiwa |
11 |
[GO] |
2021―Jul―27 |
In-silico study of peptide-protein interaction of antimicrobial peptides potentially targeting SARS and SARS-CoV-2 nucleocapsid protein |
Ritu Bansal, Sanika Mohagaonkar, Anamitra Sen, Uzma Khanam, Bhawna Rathi |
12 |
[GO] |
2021―Jul―22 |
In silico studies of Potency and safety assessment of selected trial drugs for the treatment of COVID-19 |
Peter Ifeoluwa Adegbola, Olumide Samuel Fadahunsi, Aanuoluwa Eunice Adegbola, Banjo Semire |
13 |
[GO] |
2021―Jul―19 |
Computational assessment of select antiviral phytochemicals as potential SARS-Cov-2 main protease inhibitors: molecular dynamics guided ensemble docking and extended molecular dynamics |
Sanjay Sawant, Rajesh Patil, Manoj Khawate, Vishal Zambre, Vaibhav Shilimkar, Suresh Jagtap |
14 |
[GO] |
2021―Jul―01 |
In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CLpro) and SARS-CoV-2 (Mpro) |
Gérard Vergoten, Christian Bailly |
15 |
[GO] |
2021―Jun―28 |
Prediction and identification of T cell epitopes of COVID-19 with balanced cytokine response for the development of peptide based vaccines |
Parul Bhatt, Monika Sharma, Sadhna Sharma |
16 |
[GO] |
2021―Apr―04 |
Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach |
Rajveer Singh, Anupam Gautam, Shivani Chandel, Vipul Sharma, Arijit Ghosh, Dhritiman Dey, Syamal Roy, V. Ravichandiran, Dipanjan Ghosh |
17 |
[GO] |
2021―Apr―04 |
In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach |
Shuvasish Choudhury, Debojyoti Moulick, Anupom Borah, Purbajyoti Saikia, Muhammed Khairujjaman Mazumder |
18 |
[GO] |
2021―Jan―06 |
Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis |
Ayat Ahmed Alrasheid, Mazin Yousif Babiker, Talal Ahmed Awad |
19 |
[GO] |
2021―Jan―06 |
In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (Mpro) |
Victoria Adeola Falade, Temitope Isaac Adelusi, Ibrahim Olaide Adedotun, Misbaudeen Abdul-Hammed, Teslim Alabi Lawal, Saheed Alabi Agboluaje |
20 |
[GO] |
2021―Jan―06 |
Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach |
Elijah Kolawole Oladipo, Ayodeji Folorunsho Ajayi, Olugbenga Samson Onile, Olumuyiwa Elijah Ariyo, Esther Moradeyo Jimah, Louis Odinakaose Ezediuno, Oluwadunsin Iyanuoluwa Adebayo, Emmanuel Tayo Adebayo, Aduragbemi Noah Odeyemi, Marvellous Oluwaseun Oyeleke, Moyosoluwa Precious Oyewole, Ayomide Samuel Oguntomi, Olawumi Elizabeth Akindiya, Victoria Oyetayo Aremu, Dorcas Olubunmi Aboderin, Julius Kola Oloke |
21 |
[GO] |
2020―Dez―04 |
Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study |
Reza Nejat, Ahmad Shahir Sadr |
22 |
[GO] |
2020―Nov―09 |
Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2 |
Shravan B. Rathod, Pravin B. Prajapati, Lata B. Punjabi, Kuntal N. Prajapati, Neha Chauhan, Mohmedyasin F. Mansuri |